| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |